{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T11:38:42Z","timestamp":1779881922814,"version":"3.53.1"},"reference-count":91,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T00:00:00Z","timestamp":1757894400000},"content-version":"vor","delay-in-days":14,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100006407","name":"Natural Science Foundation of Henan Province","doi-asserted-by":"publisher","award":["242300421509"],"award-info":[{"award-number":["242300421509"]}],"id":[{"id":"10.13039\/501100006407","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82370112"],"award-info":[{"award-number":["82370112"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82370143"],"award-info":[{"award-number":["82370143"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2025,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Multiple myeloma (MM) is a heterogeneous and relapse-prone hematologic malignancy that remains incurable. For newly diagnosed patients aged 70 years or younger, who are eligible for transplantation, autologous hematopoietic stem cell transplantation (auto-HSCT) is the preferred first-line treatment. In patients with high-risk multiple myeloma (HRMM), some studies have demonstrated that tandem auto-HSCT provides notable benefits over single auto-HSCT, particularly in extending progression-free survival (PFS) and overall survival (OS). Although allogeneic hematopoietic stem cell transplantation (allo-HSCT) currently offers the only potential for long-term cure in MM, its application is limited by high transplant-related mortality (TRM) and the risk of graft-versus-host disease (GVHD). In recent years, the emergence of novel therapies, including proteasome inhibitors, immunomodulatory drugs, monoclonal antibodies, and chimeric antigen receptor T-cell (CAR-T) therapy, has posed new challenges to the role of tandem auto-HSCT in MM treatment. This review aims to critically examine the efficacy differences between tandem and single auto-HSCT, and sequential allo-HSCT following auto-HSCT. Furthermore, it will rigorously evaluate the role and challenges of tandem auto-HSCT within the evolving therapeutic landscape.<\/jats:p>","DOI":"10.1007\/s00277-025-06563-z","type":"journal-article","created":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T02:51:12Z","timestamp":1757904672000},"page":"4287-4303","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Tandem autologous hematopoietic stem cell transplantation in multiple myeloma: A historical perspective and current challenges"],"prefix":"10.1007","volume":"104","author":[{"given":"Xueting","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yushan","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaomei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baijun","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,15]]},"reference":[{"issue":"10272","key":"6563_CR1","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/S0140-6736(21)00135-5","volume":"397","author":"N van de Donk","year":"2021","unstructured":"van de Donk N, Pawlyn C, Yong KL (2021) Multiple myeloma. Lancet 397(10272):410\u2013427","journal-title":"Lancet"},{"issue":"10","key":"6563_CR2","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1056\/NEJMoa1402888","volume":"371","author":"A Palumbo","year":"2014","unstructured":"Palumbo A, Cavallo F, Gay F, Di Raimondo F, Ben Yehuda D, Petrucci MT et al (2014) Autologous transplantation and maintenance therapy in multiple myeloma. N Engl J Med 371(10):895\u2013905","journal-title":"N Engl J Med"},{"key":"6563_CR3","doi-asserted-by":"crossref","unstructured":"Attal M, Harousseau JL, Stoppa AM, Sotto JJ, Fuzibet JG, Rossi JF, Intergroupe Francais du myelome et al (1996) A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N Engl J Med 335(2):91\u201397","DOI":"10.1056\/NEJM199607113350204"},{"issue":"14","key":"6563_CR4","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1056\/NEJMoa1611750","volume":"376","author":"M Attal","year":"2017","unstructured":"Attal M, Lauwers-Cances V, Hulin C, Leleu X, Caillot D, Escoffre M et al (2017) Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma. N Engl J Med 376(14):1311\u20131320","journal-title":"N Engl J Med"},{"key":"6563_CR5","doi-asserted-by":"crossref","unstructured":"Usmani SZ, Facon T, Hungria V, Bahlis NJ, Venner CP, Braunstein M et al (2025) Daratumumab plus bortezomib, Lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS trial. Nat Med","DOI":"10.1016\/S2152-2650(25)01288-1"},{"issue":"Supplement 1","key":"6563_CR6","first-page":"401","volume":"130","author":"M Cavo","year":"2017","unstructured":"Cavo M, Gay FM, Patriarca F, Zamagni E, Montefusco V, Dozza L et al (2017) Double autologous stem cell transplantation significantly prolongs Progression-Free survival and overall survival in comparison with single autotransplantation in newly diagnosed multiple myeloma: an analysis of phase 3 EMN02\/HO95 study. Blood 130(Supplement 1):401","journal-title":"Blood"},{"issue":"16","key":"6563_CR7","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1016\/S1470-2045(15)00389-7","volume":"16","author":"F Gay","year":"2015","unstructured":"Gay F, Oliva S, Petrucci MT, Conticello C, Catalano L, Corradini P et al (2015) Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial. Lancet Oncol 16(16):1617\u20131629","journal-title":"Lancet Oncol"},{"issue":"6","key":"6563_CR8","doi-asserted-by":"publisher","first-page":"e456","DOI":"10.1016\/S2352-3026(20)30099-5","volume":"7","author":"M Cavo","year":"2020","unstructured":"Cavo M, Gay F, Beksac M, Pantani L, Petrucci MT, Dimopoulos MA et al (2020) Autologous Haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and Lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02\/HO95): a multicentre, randomised, open-label, phase 3 study. Lancet Haematol 7(6):e456\u2013e68","journal-title":"Lancet Haematol"},{"issue":"8","key":"6563_CR9","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1182\/blood.2020005288","volume":"136","author":"PM Voorhees","year":"2020","unstructured":"Voorhees PM, Kaufman JL, Laubach J, Sborov DW, Reeves B, Rodriguez C et al (2020) Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial. Blood 136(8):936\u2013945","journal-title":"Blood"},{"issue":"12","key":"6563_CR10","doi-asserted-by":"publisher","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","volume":"15","author":"SV Rajkumar","year":"2014","unstructured":"Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV et al (2014) International myeloma working group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol 15(12):e538\u2013e548","journal-title":"Lancet Oncol"},{"issue":"20","key":"6563_CR11","doi-asserted-by":"publisher","first-page":"2029","DOI":"10.1182\/blood.2023023597","volume":"143","author":"C Touzeau","year":"2024","unstructured":"Touzeau C, Perrot A, Hulin C, Manier S, Macro M, Chretien ML et al (2024) Daratumumab, carfilzomib, lenalidomide, and dexamethasone with tandem transplant for high-risk newly diagnosed myeloma. Blood 143(20):2029\u20132036","journal-title":"Blood"},{"issue":"9","key":"6563_CR12","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.1002\/ajh.27422","volume":"99","author":"SV Rajkumar","year":"2024","unstructured":"Rajkumar SV (2024) Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management. Am J Hematol 99(9):1802\u20131824","journal-title":"Am J Hematol"},{"issue":"16","key":"6563_CR13","doi-asserted-by":"publisher","first-page":"1780","DOI":"10.1182\/blood.2024027342","volume":"145","author":"MA Baertsch","year":"2025","unstructured":"Baertsch MA, Schlenzka J, Hielscher T, Raab MS, Sauer S, Merz M et al (2025) Salvage autologous transplant in relapsed multiple myeloma: long-term follow-up of the phase 3 GMMG relapse trial. Blood 145(16):1780\u20131787","journal-title":"Blood"},{"key":"6563_CR14","unstructured":"Avet-Loiseau H, Davies FE, Samur MK, Corre J, D\u2019Agostino M, Kaiser MF et al (2025) International myeloma society\/international myeloma working group consensus recommendations on the definition of High-Risk multiple myeloma. J Clin Oncol. JCO2401893"},{"key":"6563_CR15","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-025-01639-5","author":"B Mohan Lal","year":"2025","unstructured":"Mohan Lal B, van Rhee F, Al Hadidi S (2025) Current state of evidence on definitions and management of high-risk multiple myeloma. Curr Oncol Rep. https:\/\/doi.org\/10.1007\/s11912-025-01639-5","journal-title":"Curr Oncol Rep"},{"issue":"3","key":"6563_CR16","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1111\/bjh.16793","volume":"193","author":"C Bygrave","year":"2021","unstructured":"Bygrave C, Pawlyn C, Davies F, Craig Z, Cairns D, Hockaday A et al (2021) Early relapse after high-dose melphalan autologous stem cell transplant predicts inferior survival and is associated with high disease burden and genetically high\u2010risk disease in multiple myeloma. Br J Haematol 193(3):551\u2013555","journal-title":"Br J Haematol"},{"key":"6563_CR17","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1182\/blood-2019-129431","volume":"134","author":"A Spencer","year":"2019","unstructured":"Spencer A, Mollee P, Blacklock HA, Harrison S, Quach H, Ho PJ et al (2019) Real-world outcome for newly diagnosed patients with functional high-risk myeloma-a myeloma and related diseases registry analysis. Blood 134:269","journal-title":"Blood"},{"issue":"7","key":"6563_CR18","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/j.clml.2019.10.014","volume":"20","author":"E Kastritis","year":"2020","unstructured":"Kastritis E, Roussou M, Eleutherakis-Papaiakovou E, Gavriatopoulou M, Migkou M, Gika D et al (2020) Early relapse after autologous transplant is associated with very poor survival and identifies an ultra-high-risk group of patients with myeloma. Clin Lymphoma Myeloma Leuk 20(7):445\u2013452","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"4","key":"6563_CR19","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1038\/leu.2017.331","volume":"32","author":"SK Kumar","year":"2018","unstructured":"Kumar SK, Dispenzieri A, Fraser R, Mingwei F, Akpek G, Cornell R et al (2018) Early relapse after autologous hematopoietic cell transplantation remains a poor prognostic factor in multiple myeloma but outcomes have improved over time. Leukemia 32(4):986\u2013995","journal-title":"Leukemia"},{"issue":"1","key":"6563_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00576-3","volume":"12","author":"CY Soekojo","year":"2022","unstructured":"Soekojo CY, Chung TH, Furqan MS, Chng WJ (2022) Genomic characterization of functional high-risk multiple myeloma patients. Blood Cancer J 12(1):24","journal-title":"Blood Cancer J"},{"issue":"3","key":"6563_CR21","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1111\/bjh.19578","volume":"205","author":"S Lim","year":"2024","unstructured":"Lim S, Reynolds J, Quach H, Hutchinson A, Kerridge I, Janowski W et al (2024) Response adaptive salvage treatment with daratumumab-lenalidomide-dexamethasone for newly diagnosed transplant-eligible multiple myeloma patients failing front-line bortezomib-based induction therapy-ALLG MM21. Br J Haematol 205(3):900\u2013914","journal-title":"Br J Haematol"},{"key":"6563_CR22","doi-asserted-by":"publisher","unstructured":"Kaiser MF, Sonneveld P, Cairns DA, Raab MS, San-Miguel Izquierdo J, Zhang R et al (2025) Co-occurrence of cytogenetic abnormalities and high-risk disease in newly diagnosed and relapsed\/refractory multiple myeloma. J Clin Oncol. https:\/\/doi.org\/10.1200\/JCO-24-01253","DOI":"10.1200\/JCO-24-01253"},{"issue":"11","key":"6563_CR23","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1182\/blood.2022017863","volume":"141","author":"A Schavgoulidze","year":"2023","unstructured":"Schavgoulidze A, Talbot A, Perrot A, Cazaubiel T, Leleu X, Manier S et al (2023) Biallelic deletion of 1p32 defines ultra-high-risk myeloma, but monoallelic del(1p32) remains a strong prognostic factor. Blood 141(11):1308\u20131315","journal-title":"Blood"},{"issue":"3","key":"6563_CR24","doi-asserted-by":"publisher","first-page":"e433520","DOI":"10.1200\/EDBK_433520","volume":"44","author":"MJ Rees","year":"2024","unstructured":"Rees MJ, D\u2019Agostino M, Leypoldt LB, Kumar S, Weisel KC, Gay F (2024) Navigating high-risk and ultrahigh-risk multiple myeloma: challenges and emerging strategies. Am Soc Clin Oncol Educ Book 44(3):e433520","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"23","key":"6563_CR25","doi-asserted-by":"publisher","first-page":"3945","DOI":"10.1200\/JCO.22.02567","volume":"41","author":"MF Kaiser","year":"2023","unstructured":"Kaiser MF, Hall A, Walker K, Sherborne A, De Tute RM, Newnham N et al (2023) Daratumumab, cyclophosphamide, bortezomib, lenalidomide, and dexamethasone as induction and extended consolidation improves outcome in ultra-high-risk multiple myeloma. J Clin Oncol 41(23):3945\u20133955","journal-title":"J Clin Oncol"},{"issue":"1","key":"6563_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-62885-0","volume":"10","author":"M Baysal","year":"2020","unstructured":"Baysal M, Demirci U, Umit E, Kirkizlar HO, Atli EI, Gurkan H et al (2020) Concepts of double hit and triple hit disease in multiple myeloma, entity and prognostic significance. Sci Rep 10(1):5991","journal-title":"Sci Rep"},{"issue":"1","key":"6563_CR27","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/S1470-2045(22)00693-3","volume":"24","author":"R Mina","year":"2023","unstructured":"Mina R, Musto P, Rota-Scalabrini D, Paris L, Gamberi B, Palmas A et al (2023) Carfilzomib induction, consolidation, and maintenance with or without autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma: pre-planned cytogenetic subgroup analysis of the randomised, phase 2 FORTE trial. Lancet Oncol 24(1):64\u201376","journal-title":"Lancet Oncol"},{"issue":"2","key":"6563_CR28","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1056\/NEJMoa2204925","volume":"387","author":"PG Richardson","year":"2022","unstructured":"Richardson PG, Jacobus SJ, Weller EA, Hassoun H, Lonial S, Raje NS et al (2022) Triplet therapy, transplantation, and maintenance until progression in myeloma. N Engl J Med 387(2):132\u2013147","journal-title":"N Engl J Med"},{"issue":"23","key":"6563_CR29","doi-asserted-by":"publisher","first-page":"5988","DOI":"10.1182\/bloodadvances.2020002827","volume":"4","author":"NC Munshi","year":"2020","unstructured":"Munshi NC, Avet-Loiseau H, Anderson KC, Neri P, Paiva B, Samur M et al (2020) A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma. Blood Adv 4(23):5988\u20135999","journal-title":"Blood Adv"},{"issue":"3","key":"6563_CR30","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1002\/cyto.b.21755","volume":"96","author":"G Rossi","year":"2019","unstructured":"Rossi G, Falcone AP, Minervini MM, De Cillis GP, De Waure C, Sisti LG et al (2019) Minimal residual disease and log-reduction of plasma cells are associated with superior response after double autologous stem cell transplant in younger patients with multiple myeloma. Cytometry B Clin Cytom 96(3):195\u2013200","journal-title":"Cytometry B Clin Cytom"},{"issue":"6","key":"6563_CR31","doi-asserted-by":"publisher","first-page":"E195","DOI":"10.1002\/ajh.26530","volume":"97","author":"M Mohan","year":"2022","unstructured":"Mohan M, Gundarlapalli S, Szabo A, Yarlagadda N, Kakadia S, Konda M et al (2022) Tandem autologous stem cell transplantation in patients with persistent bone marrow minimal residual disease after first transplantation in multiple myeloma. Am J Hematol 97(6):E195\u2013E8","journal-title":"Am J Hematol"},{"issue":"1","key":"6563_CR32","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s12185-023-03682-z","volume":"119","author":"K Suzuki","year":"2024","unstructured":"Suzuki K, Gunji T, Kawashima M, Uryu H, Nagao R, Momoki M et al (2024) Contribution of post-transplantation therapy to sustained MRD negativity in multiple myeloma: a retrospective analysis. Int J Hematol 119(1):39\u201349","journal-title":"Int J Hematol"},{"issue":"1","key":"6563_CR33","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1200\/JCO.23.01696","volume":"42","author":"LB Leypoldt","year":"2024","unstructured":"Leypoldt LB, Tichy D, Besemer B, Hanel M, Raab MS, Mann C et al (2024) Isatuximab, carfilzomib, lenalidomide, and dexamethasone for the treatment of high-risk newly diagnosed multiple myeloma. J Clin Oncol 42(1):26\u201337","journal-title":"J Clin Oncol"},{"issue":"Supplement 1","key":"6563_CR34","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1182\/blood-2023-177546","volume":"142","author":"F Gay","year":"2023","unstructured":"Gay F, Roeloffzen W, Dimopoulos M, Rosi\u00f1ol L, Klift Mvd, Mina R et al (2023) Results of the phase III randomized Iskia trial: Isatuximab-Carfilzomib-Lenalidomide-Dexamethasone vs Carfilzomib-Lenalidomide-Dexamethasone as Pre-Transplant induction and Post-Transplant consolidation in newly diagnosed multiple myeloma patients. Blood 142(Supplement 1):4","journal-title":"Blood"},{"issue":"10","key":"6563_CR35","doi-asserted-by":"publisher","first-page":"e825","DOI":"10.1016\/S2352-3026(23)00217-X","volume":"10","author":"PM Voorhees","year":"2023","unstructured":"Voorhees PM, Sborov DW, Laubach J, Kaufman JL, Reeves B, Rodriguez C et al (2023) Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): final analysis of an open-label, randomised, phase 2 trial. Lancet Haematol 10(10):e825\u2013e37","journal-title":"Lancet Haematol"},{"issue":"2","key":"6563_CR36","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1007\/s11899-021-00633-5","volume":"16","author":"L Bertamini","year":"2021","unstructured":"Bertamini L, D\u2019Agostino M, Gay F (2021) MRD assessment in multiple myeloma: progress and challenges. Curr Hematol Malig Rep 16(2):162\u2013171","journal-title":"Curr Hematol Malig Rep"},{"key":"6563_CR37","doi-asserted-by":"publisher","first-page":"4716","DOI":"10.1182\/blood-2023-190487","volume":"142","author":"L Campbell","year":"2023","unstructured":"Campbell L, Ramasamy K, Sadler R, Non-Invasive MRD (2023) Monitoring in multiple myeloma patients by heavy\/light chain analysis. Blood 142:4716","journal-title":"Blood"},{"key":"6563_CR38","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V79.11.2827.2827","author":"J Harousseau","year":"1992","unstructured":"Harousseau J, Milpied N, Laporte J, Collombat P, Facon T, Tigaud J et al (1992) Double-intensive therapy in high-risk multiple myeloma. Blood. https:\/\/doi.org\/10.1182\/blood.V79.11.2827.2827","journal-title":"Blood"},{"issue":"26","key":"6563_CR39","doi-asserted-by":"publisher","first-page":"2495","DOI":"10.1056\/NEJMoa032290","volume":"349","author":"M Attal","year":"2003","unstructured":"Attal M, Harousseau J-L, Facon T, Guilhot F, Doyen C, Fuzibet J-G et al (2003) Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med 349(26):2495\u20132502","journal-title":"N Engl J Med"},{"issue":"17","key":"6563_CR40","doi-asserted-by":"publisher","first-page":"2434","DOI":"10.1200\/JCO.2006.10.2509","volume":"25","author":"M Cavo","year":"2007","unstructured":"Cavo M, Tosi P, Zamagni E, Cellini C, Tacchetti P, Patriarca F et al (2007) Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 clinical study. J Clin Oncol 25(17):2434\u20132441","journal-title":"J Clin Oncol"},{"issue":"1","key":"6563_CR41","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-024-00529-7","volume":"10","author":"F Malard","year":"2024","unstructured":"Malard F, Neri P, Bahlis NJ, Terpos E, Moukalled N, Hungria VTM et al (2024) Multiple myeloma. Nat Rev Dis Primers 10(1):45","journal-title":"Nat Rev Dis Primers"},{"issue":"21","key":"6563_CR42","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1182\/blood.V122.21.767.767","volume":"122","author":"M Cavo","year":"2013","unstructured":"Cavo M, Salwender H, Rosi\u00f1ol L, Moreau P, Petrucci MT, Blau IW et al (2013) Double vs single autologous stem cell transplantation after bortezomib-based induction regimens for multiple myeloma: an integrated analysis of patient-level data from phase European III studies. Blood 122(21):767","journal-title":"Blood"},{"issue":"21","key":"6563_CR43","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1182\/blood.V122.21.404.404","volume":"122","author":"P Sonneveld","year":"2013","unstructured":"Sonneveld P, Scheid C, van der Holt B, Jarari Le, Bertsch U, Salwender H et al (2013) Bortezomib induction and maintenance treatment improves survival in patients with newly diagnosed multiple myeloma:extended Follow-Up of the HOVON-65\/GMMG-HD4 trial. Blood 122(21):404","journal-title":"Blood"},{"issue":"7","key":"6563_CR44","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1200\/JCO.18.00685","volume":"37","author":"EA Stadtmauer","year":"2019","unstructured":"Stadtmauer EA, Pasquini MC, Blackwell B, Hari P, Bashey A, Devine S et al (2019) Autologous transplantation, consolidation, and maintenance therapy in multiple myeloma: results of the BMT CTN 0702 trial. J Clin Oncol 37(7):589\u2013597","journal-title":"J Clin Oncol"},{"issue":"22","key":"6563_CR45","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V128.22.LBA-1.LBA-1","volume":"128","author":"EA Stadtmauer","year":"2016","unstructured":"Stadtmauer EA, Pasquini MC, Blackwell B, Knust K, Bashey A, Devine SM et al (2016) Comparison of autologous hematopoietic cell transplant (autoHCT), bortezomib, lenalidomide (Len) and dexamethasone (RVD) consolidation with Len maintenance (ACM), tandem autohct with Len maintenance (TAM) and autohct with Len maintenance (AM) for up-front treatment of patients with multiple myeloma (MM): primary results from the randomized phase III trial of the blood and marrow transplant clinical trials network (BMT CTN 0702. Blood 128(22):LBA\u20131","journal-title":"Blood"},{"issue":"14","key":"6563_CR46","doi-asserted-by":"publisher","first-page":"3438","DOI":"10.1080\/10428194.2022.2123229","volume":"63","author":"A Villalba","year":"2022","unstructured":"Villalba A, Gonzalez-Rodriguez AP, Arzuaga-Mendez J, Puig N, Arnao M, Arguinano JM et al (2022) Single versus tandem autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma and high-risk cytogenetics. A retrospective, open-label study of the pethema\/spanish myeloma group (GEM). Leuk Lymphoma 63(14):3438\u20133447","journal-title":"Leuk Lymphoma"},{"key":"6563_CR47","unstructured":"Philip SA, Lam S, Phua C, Louzada M, Xenocostas A, Deotare U (eds) (2022) Tandem Meetings, Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR"},{"key":"6563_CR48","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-199908","author":"G An","year":"2024","unstructured":"An G, Liu Z, Jin J, Cai Z, Li W, Xia Z et al (2024) Isatuximab plus bortezomib, lenalidomide, and dexamethasone (Isa-VRd) versus vrd in Chinese patients with newly diagnosed multiple myeloma who are ineligible for transplant: IMROZ subgroup analysis. Blood. https:\/\/doi.org\/10.1182\/blood-2024-199908","journal-title":"Blood"},{"issue":"10","key":"6563_CR49","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1016\/S1470-2045(21)00428-9","volume":"22","author":"P Moreau","year":"2021","unstructured":"Moreau P, Hulin C, Perrot A, Arnulf B, Belhadj K, Benboubker L et al (2021) Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trial. Lancet Oncol 22(10):1378\u20131390","journal-title":"Lancet Oncol"},{"issue":"9","key":"6563_CR50","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-020-00357-4","volume":"10","author":"MA Dimopoulos","year":"2020","unstructured":"Dimopoulos MA, Lonial S, White D, Moreau P, Weisel K, San-Miguel J et al (2020) Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study. Blood Cancer J 10(9):91","journal-title":"Blood Cancer J"},{"issue":"3","key":"6563_CR51","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1200\/JCO.21.02815","volume":"41","author":"MA Dimopoulos","year":"2023","unstructured":"Dimopoulos MA, Dytfeld D, Grosicki S, Moreau P, Takezako N, Hori M et al (2023) Elotuzumab plus pomalidomide and dexamethasone for relapsed\/refractory multiple myeloma: final overall survival analysis from the randomized phase II eloquent-3 trial. J Clin Oncol 41(3):568\u2013578","journal-title":"J Clin Oncol"},{"issue":"4","key":"6563_CR52","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1007\/s15015-023-3188-0","volume":"26","author":"R W\u00e4sch","year":"2023","unstructured":"W\u00e4sch R, Engelhardt M (2023) Neue Daten Zur therapie des multiplen myeloms, Hodgkin-Lymphoms, DLBCL und MDS. Im Fokus Onkologie 26(4):28\u201331","journal-title":"Im Fokus Onkologie"},{"key":"6563_CR53","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1182\/blood-2021-147323","volume":"138","author":"H Goldschmidt","year":"2021","unstructured":"Goldschmidt H, Mai EK, Bertsch U, Besemer B, Haenel M, Miah K et al (2021) Elotuzumab in combination with lenalidomide, bortezomib, dexamethasone and autologous transplantation for newly-diagnosed multiple myeloma: results from the randomized phase III GMMG-HD6 trial. Blood 138:486","journal-title":"Blood"},{"issue":"30","key":"6563_CR54","doi-asserted-by":"publisher","first-page":"4630","DOI":"10.1200\/JCO.2010.28.3945","volume":"28","author":"H Avet-Loiseau","year":"2010","unstructured":"Avet-Loiseau H, Leleu X, Roussel M, Moreau P, Guerin-Charbonnel C, Caillot D et al (2010) Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p). J Clin Oncol 28(30):4630\u20134634","journal-title":"J Clin Oncol"},{"key":"6563_CR55","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1182\/blood-2023-174044","volume":"142","author":"C Touzeau","year":"2023","unstructured":"Touzeau C, Perrot A, Hulin C, Manier S, Macro M, Chretien M-L et al (2023) Daratumumab, carfilzomib, lenalidomide, and dexamethasone induction and consolidation with tandem transplant in high-risk newly diagnosed myeloma patients: final results of the phase 2 study IFM 2018-04. Blood 142:207","journal-title":"Blood"},{"issue":"2","key":"6563_CR56","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/s41571-020-0427-6","volume":"18","author":"L Mikkilineni","year":"2021","unstructured":"Mikkilineni L, Kochenderfer JN (2021) CAR T cell therapies for patients with multiple myeloma. Nat Rev Clin Oncol 18(2):71\u201384","journal-title":"Nat Rev Clin Oncol"},{"issue":"13","key":"6563_CR57","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1182\/blood-2016-04-711903","volume":"128","author":"SA Ali","year":"2016","unstructured":"Ali SA, Shi V, Maric I, Wang M, Stroncek DF, Rose JJ et al (2016) T cells expressing an anti\u2013B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma. Blood 128(13):1688\u20131700","journal-title":"Blood"},{"issue":"10","key":"6563_CR58","doi-asserted-by":"publisher","first-page":"3691","DOI":"10.1002\/bit.27882","volume":"118","author":"M Sadeqi Nezhad","year":"2021","unstructured":"Sadeqi Nezhad M, Yazdanifar M, Abdollahpour-Alitappeh M, Sattari A, Seifalian A, Bagheri N (2021) Strengthening the CAR-T cell therapeutic application using CRISPR\/Cas9 technology. Biotechnol Bioeng 118(10):3691\u20133705","journal-title":"Biotechnol Bioeng"},{"issue":"11","key":"6563_CR59","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1056\/NEJMoa1504542","volume":"373","author":"AL Garfall","year":"2015","unstructured":"Garfall AL, Maus MV, Hwang WT, Lacey SF, Mahnke YD, Melenhorst JJ et al (2015) Chimeric antigen receptor T cells against CD19 for multiple myeloma. N Engl J Med 373(11):1040\u20131047","journal-title":"N Engl J Med"},{"key":"6563_CR60","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2022.215721","volume":"549","author":"R Huang","year":"2022","unstructured":"Huang R, Wang X, Zhang X (2022) Unity brings strength: combination of CAR-T cell therapy and HSCT. Cancer Lett 549:215721","journal-title":"Cancer Lett"},{"key":"6563_CR61","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.120505","author":"AL Garfall","year":"2018","unstructured":"Garfall AL, Stadtmauer EA, Hwang WT, Lacey SF, Melenhorst JJ, Krevvata M et al (2018) Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma. JCI Insight. https:\/\/doi.org\/10.1172\/jci.insight.120505","journal-title":"JCI Insight"},{"key":"6563_CR62","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1182\/blood-2023-178882","volume":"142","author":"J Hillengass","year":"2023","unstructured":"Hillengass J, Cohen AD, Agha ME, Delforge M, Kerre T, Roeloffzen W et al (2023) The phase 2 CARTITUDE-2 trial: updated efficacy and safety of ciltacabtagene autoleucel in patients with multiple myeloma and 1\u20133 prior lines of therapy (cohort A) and with early relapse after first line treatment (cohort B). Blood 142:1021","journal-title":"Blood"},{"issue":"15suppl","key":"6563_CR63","doi-asserted-by":"publisher","first-page":"8007","DOI":"10.1200\/JCO.2021.39.15_suppl.8007","volume":"39","author":"A Krishnan","year":"2021","unstructured":"Krishnan A, Garfall A, Mateos M, Donk NVD, Nahi H, San-Miguel J et al (2021) Updated phase 1 results of teclistamab, a B-cell maturation antigen (BCMA) \u00d7 CD3 bispecific antibody, in relapsed\/refractory multiple myeloma (MM). J Clin Oncol 39(15suppl):8007","journal-title":"J Clin Oncol"},{"issue":"18","key":"6563_CR64","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1056\/NEJMc2211969","volume":"387","author":"ERS Cliff","year":"2022","unstructured":"Cliff ERS, Mian H, Mohyuddin GR (2022) Teclistamab in relapsed or refractory multiple myeloma. N Engl J Med 387(18):1721\u20131722","journal-title":"N Engl J Med"},{"issue":"9","key":"6563_CR65","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1038\/s41591-023-02528-9","volume":"29","author":"AM Lesokhin","year":"2023","unstructured":"Lesokhin AM, Tomasson MH, Arnulf B, Bahlis NJ, Miles Prince H, Niesvizky R et al (2023) Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results. Nat Med 29(9):2259\u20132267","journal-title":"Nat Med"},{"issue":"23","key":"6563_CR66","doi-asserted-by":"publisher","first-page":"2389","DOI":"10.1182\/blood.2024024582","volume":"144","author":"S Ailawadhi","year":"2024","unstructured":"Ailawadhi S, Arnulf B, Patel K, Cavo M, Nooka AK, Manier S et al (2024) Ide-cel vs standard regimens in triple-class-exposed relapsed and refractory multiple myeloma: updated KarMMa-3 analyses. Blood 144(23):2389\u20132401","journal-title":"Blood"},{"key":"6563_CR67","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1408892","volume":"15","author":"DK Hansen","year":"2024","unstructured":"Hansen DK, Lu X, Puglianini OC, Sorensen S, Usmani SZ, Zhang E et al (2024) Cost-per-responder analysis of patients with lenalidomide-refractory multiple myeloma receiving ciltacabtagene autoleucel in CARTITUDE-4. Front Immunol 15:1408892","journal-title":"Front Immunol"},{"issue":"22","key":"6563_CR68","doi-asserted-by":"publisher","first-page":"2320","DOI":"10.1182\/blood.V114.22.2320.2320","volume":"114","author":"J-P Fermand","year":"2009","unstructured":"Fermand J-P, Desseaux K, Marolleau JP (2009) Single versus tandem high dose therapy (HDT) supported with autologous blood stem cell (ABSC) transplantation using unselected or CD34-enriched ABSC: long-term results of a two by two designed randomized trial in 225 young patients with multiple myeloma (MM). Blood 114(22):2320","journal-title":"Blood"},{"issue":"5","key":"6563_CR69","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1111\/bjh.13994","volume":"173","author":"EK Mai","year":"2016","unstructured":"Mai EK, Benner A, Bertsch U, Brossart P, Hanel A, Kunzmann V et al (2016) Single versus tandem high-dose melphalan followed by autologous blood stem cell transplantation in multiple myeloma: long-term results from the phase III GMMG-HD2 trial. Br J Haematol 173(5):731\u2013741","journal-title":"Br J Haematol"},{"issue":"2","key":"6563_CR70","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1093\/jnci\/djn439","volume":"101","author":"A Kumar","year":"2009","unstructured":"Kumar A, Kharfan-Dabaja MA, Glasmacher A, Djulbegovic B (2009) Tandem versus single autologous hematopoietic cell transplantation for the treatment of multiple myeloma: a systematic review and meta-analysis. J Natl Cancer Inst 101(2):100\u2013106","journal-title":"J Natl Cancer Inst"},{"key":"6563_CR71","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2024.06.030","author":"CP Venner","year":"2024","unstructured":"Venner CP, Duggan P, Song K, Reece D, Sharma S, Su J et al (2024) Tandem autologous stem cell transplantation does not benefit high-risk myeloma patients in the maintenance era: real-world results from the Canadian Myeloma Research Group database. Transplant Cell Ther. https:\/\/doi.org\/10.1016\/j.jtct.2024.06.030","journal-title":"Transplant Cell Ther"},{"issue":"8","key":"6563_CR72","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1016\/S1470-2045(24)00282-1","volume":"25","author":"P Moreau","year":"2024","unstructured":"Moreau P, Hulin C, Perrot A, Arnulf B, Belhadj K, Benboubker L et al (2024) Bortezomib, thalidomide, and dexamethasone with or without daratumumab and followed by daratumumab maintenance or observation in transplant-eligible newly diagnosed multiple myeloma: long-term follow-up of the CASSIOPEIA randomised controlled phase 3 trial. Lancet Oncol 25(8):1003\u20131014","journal-title":"Lancet Oncol"},{"issue":"4","key":"6563_CR73","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1056\/NEJMoa2312054","volume":"390","author":"P Sonneveld","year":"2024","unstructured":"Sonneveld P, Dimopoulos MA, Boccadoro M, Quach H, Ho PJ, Beksac M et al (2024) Daratumumab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med 390(4):301\u2013313","journal-title":"N Engl J Med"},{"issue":"1","key":"6563_CR74","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.70573","volume":"14","author":"X Dou","year":"2025","unstructured":"Dou X, Ren J, Li J, Liu X, Bao L, Chen Y et al (2025) Tandem Versus Single Autologous Stem Cell Transplantation for High\u2010Risk Multiple Myeloma in the Era\u00a0of Novel Agents: A Real\u2010World Study of China. Cancer Med 14(1):e70573","journal-title":"Cancer Med"},{"issue":"11","key":"6563_CR75","doi-asserted-by":"publisher","first-page":"4362","DOI":"10.1182\/blood-2003-11-3862","volume":"103","author":"HM Lokhorst","year":"2004","unstructured":"Lokhorst HM, Wu K, Verdonck LF, Laterveer LL, van de Donk NW, van Oers MH et al (2004) The occurrence of graft-versus-host disease is the major predictive factor for response to donor lymphocyte infusions in multiple myeloma. Blood 103(11):4362\u20134364","journal-title":"Blood"},{"issue":"3","key":"6563_CR76","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1182\/blood.V87.3.1196.bloodjournal8731196","volume":"87","author":"G Tricot","year":"1996","unstructured":"Tricot G, Vesole DH, Jagannath S, Hilton J, Munshi N, Barlogie B (1996) Graft-versus-myeloma effect: proof of principle. Blood 87(3):1196\u20131198","journal-title":"Blood"},{"issue":"9","key":"6563_CR77","doi-asserted-by":"publisher","first-page":"3474","DOI":"10.1182\/blood-2005-09-3869","volume":"107","author":"F Garban","year":"2006","unstructured":"Garban F, Attal M, Michallet M, Hulin C, Bourhis JH, Yakoub-Agha I et al (2006) Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma. Blood 107(9):3474\u20133480","journal-title":"Blood"},{"issue":"5","key":"6563_CR78","first-page":"1469","volume":"109","author":"N Kroger","year":"2024","unstructured":"Kroger N, Wulf G, Hegenbart U, Burchert A, Stelljes M, Gagelmann N et al (2024) Autologous-allogeneic versus autologous tandem stem cell transplantation and maintenance therapy with thalidomide for multiple myeloma patients under 60 years of age: a prospective, phase II study. Haematologica 109(5):1469\u20131479","journal-title":"Haematologica"},{"issue":"4","key":"6563_CR79","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1016\/j.bbmt.2019.11.018","volume":"26","author":"S Giralt","year":"2020","unstructured":"Giralt S, Costa LJ, Maloney D, Krishnan A, Fei M, Antin JH et al (2020) Tandem autologous-autologous versus autologous-allogeneic hematopoietic stem cell transplant for patients with multiple myeloma: long-term follow-up results from the blood and marrow transplant clinical trials network 0102 trial. Biol Blood Marrow Transplant 26(4):798\u2013804","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"6563_CR80","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1038\/s41409-020-01007-w","volume":"56","author":"N Gagelmann","year":"2021","unstructured":"Gagelmann N, Eikema D-J, De Wreede LC, Rambaldi A, Iacobelli S, Koster L et al (2021) Upfront stem cell transplantation for newly diagnosed multiple myeloma with del(17p) and t(4;14): a study from the CMWP-EBMT. Bone Marrow Transplant 56(1):210\u2013217","journal-title":"Bone Marrow Transplant"},{"issue":"22","key":"6563_CR81","doi-asserted-by":"publisher","first-page":"3016","DOI":"10.1200\/JCO.2010.32.7312","volume":"29","author":"B Bjorkstrand","year":"2011","unstructured":"Bjorkstrand B, Iacobelli S, Hegenbart U, Gruber A, Greinix H, Volin L et al (2011) Tandem autologous\/reduced-intensity conditioning allogeneic stem-cell transplantation versus autologous transplantation in myeloma: long-term follow-up. J Clin Oncol 29(22):3016\u20133022","journal-title":"J Clin Oncol"},{"issue":"11","key":"6563_CR82","doi-asserted-by":"publisher","first-page":"2710","DOI":"10.1038\/s41375-019-0537-2","volume":"33","author":"S Knop","year":"2019","unstructured":"Knop S, Engelhardt M, Liebisch P, Meisner C, Holler E, Metzner B et al (2019) Allogeneic transplantation in multiple myeloma: long-term follow-up and cytogenetic subgroup analysis. Leukemia 33(11):2710\u20132719","journal-title":"Leukemia"},{"key":"6563_CR83","doi-asserted-by":"crossref","unstructured":"Krishnan A, Pasquini MC, Logan B, Stadtmauer EA, Vesole DH, Alyea E 3 et al (2011) Autologous Haemopoietic stem-cell transplantation followed by allogeneic or autologous Haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial. Lancet Oncol 12(13):1195\u20131203","DOI":"10.1016\/S1470-2045(11)70243-1"},{"issue":"9","key":"6563_CR84","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1038\/s41409-020-0887-4","volume":"55","author":"LJ Costa","year":"2020","unstructured":"Costa LJ, Iacobelli S, Pasquini MC, Modi R, Giaccone L, Blade J et al (2020) Long-term survival of 1338 MM patients treated with tandem autologous vs. autologous-allogeneic transplantation. Bone Marrow Transplant 55(9):1810\u20131816","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"6563_CR85","doi-asserted-by":"publisher","DOI":"10.1080\/16078454.2023.2269509","volume":"28","author":"M Wei","year":"2023","unstructured":"Wei M, Xie C, Huang J, Liu Q, Lai Y (2023) Autologous followed by allogeneic versus tandem-autologous transplantation in high-risk, newly diagnosed multiple myeloma: a systematic review and meta-analysis. Hematology 28(1):2269509","journal-title":"Hematology"},{"issue":"Supplement 1","key":"6563_CR86","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1182\/blood-2021-146060","volume":"138","author":"T Martin","year":"2021","unstructured":"Martin T, Usmani SZ, Berdeja JG, Jakubowiak A, Agha M, Cohen AD et al (2021) Updated results from CARTITUDE-1: phase 1b\/2Study of ciltacabtagene autoleucel, a B-Cell maturation antigen-Directed chimeric antigen receptor T cell therapy, in patients with relapsed\/refractory multiple myeloma. Blood 138(Supplement 1):549","journal-title":"Blood"},{"issue":"1","key":"6563_CR87","doi-asserted-by":"publisher","first-page":"e35665","DOI":"10.1002\/cncr.35665","volume":"131","author":"Z Cai","year":"2025","unstructured":"Cai Z, Xia Z, He AL, Dong YJ, Wang Y, Liao A et al (2025) Efficacy, safety, and pharmacokinetics of Teclistamab in Chinese patients with relapsed\/refractory multiple myeloma from the China cohort of MajesTEC-1. Cancer 131(1):e35665","journal-title":"Cancer"},{"issue":"Supplement 1","key":"6563_CR88","doi-asserted-by":"publisher","first-page":"3186","DOI":"10.1182\/blood-2018-99-119873","volume":"132","author":"DH Bruinink","year":"2018","unstructured":"Bruinink DH, Duin MV, Beksa\u00e7 M, Driessen C, Ludwig H, Vermeulen M et al (2018) Differential effect of upfront intensification treatment in genetically defined myeloma risk Groups - a combined analysis of ISS, Del17p and SKY92 scores in the EMN-02\/HOVON-95 MM trial. Blood 132(Supplement 1):3186","journal-title":"Blood"},{"issue":"Supplement 1","key":"6563_CR89","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1182\/blood-2024-198638","volume":"144","author":"N Grieb","year":"2024","unstructured":"Grieb N, Oeser A, Ferle M, Hanke F, Flossdorf S, Sauer S et al (2024) Single vs. tandem autologous stem cell transplantation in newly diagnosed multiple myeloma: a real-world multi-center study from the German registry for hematopoietic stem cell transplantation and cell therapy (DRST). Blood 144(Supplement 1):708","journal-title":"Blood"},{"issue":"Supplement 1","key":"6563_CR90","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1182\/blood-2024-206003","volume":"144","author":"M Raab","year":"2024","unstructured":"Raab M, Weinhold N, Kort\u00fcm KM, Kr\u00f6nke J, Podola L, Bertsch U et al (2024) Phase 2 study of Teclistamab-Based induction regimens in patients with Transplant-Eligible (TE) newly diagnosed multiple myeloma (NDMM): results from the GMMG-HD10\/DSMM-XX (MajesTEC-5) trial. Blood 144(Supplement 1):493","journal-title":"Blood"},{"issue":"Supplement 1","key":"6563_CR91","doi-asserted-by":"publisher","first-page":"7289","DOI":"10.1182\/blood-2022-159756","volume":"140","author":"E Zamagni","year":"2022","unstructured":"Zamagni E, Boccadoro M, Spencer A, Delforge M, Reece DE, Gyula Szabo A et al (2022) MajesTEC-4 (EMN30): a phase 3 trial of teclistamab\u2009+ Lenalidomide versus Lenalidomide alone as maintenance therapy following autologous stem cell transplantation in patients with newly diagnosed multiple myeloma. Blood 140(Supplement 1):7289\u20137291","journal-title":"Blood"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06563-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-025-06563-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06563-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T06:02:51Z","timestamp":1761285771000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-025-06563-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":91,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["6563"],"URL":"https:\/\/doi.org\/10.1007\/s00277-025-06563-z","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"16 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All figures were created with Biorender (\n                      \n                      ), and publication permissions have been obtained.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}]}}